2008-07-09 23:52:10 -
- BioMarker Strategies, a Baltimore-based cancer diagnostics and medical device company, has named Karen Olson as its new Chief Executive Officer. Olson is the former president and CEO of Adhesives Research, a $115 million multinational specialty chemical and drug delivery company which was the first company to successfully develop medicated dissolvable thin strips.
"We are very pleased that a
seasoned leader with such strong executive credentials and biotech experience has agreed to join our team as CEO," said Scott Allocco, President and a co-founder of BioMarker Strategies. "Karen has been a valuable advisor to BioMarker Strategies as a board member and we welcome her leadership to direct the development our SnapPath(TM) system, negotiate strategic alliances and help us establish a dominant position in the field of tissue-based cancer diagnostics."
"With our talented scientific team and innovative technology, BioMarker Strategies is in a strong position to improve the diagnosis and treatment of cancer," said Ms. Olson. "We also have a unique opportunity to establish our SnapPath(TM) technology as an essential tool in the rapidly emerging field of personalized medicine."
Ms. Olson serves on the boards of directors of several private companies and non-profit organizations, including Loyola College's Sellinger Business School Board of Sponsors. In addition to holding an executive MBA from Loyola College, a BS in chemistry and a BS in medical technology from California Lutheran University, she is currently completing her MS degree in biotechnology at Johns Hopkins University. She is also an instructor of the national, awarding winning ACTiVATE program at University of Maryland, Baltimore County. Olson has received numerous honors for her professional achievements, including Ernst & Young's Maryland Entrepreneur of the Year, Smart Woman's Woman of the Year and The Baltimore Daily Record's Healthcare Leader of the Year finalist.
In addition to naming Olson CEO, the company also announced that its scientific founder, Dr. Douglas Clark, will relinquish his role as CEO to become Chief Science Officer (CSO). Dr. Clark, who will retain his position as Chairman of the Board, is a national expert on cytopathology and tumor tissue-based biomarkers. Dr. Kathleen Murphy, who is also a founding member of the company, will relinquish her role as CSO to become a member of the company's Scientific Advisory Committee.
BioMarker Strategies (www.biomarkerstrategies.com) is developing the novel SnapPath(TM) tumor cell processing and testing system to improve the diagnosis and treatment of cancer. The SnapPath(TM) system is a pathology-based medical device that preserves the biological integrity of tumor cells obtained from biopsies and optimizes them for molecular biomarker analysis.
BioMarker Strategies
Scott Allocco, President
410-532-2641
